Tags

Type your tag names separated by a space and hit enter

Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy.
Immun Inflamm Dis. 2018 12; 6(4):456-464.II

Abstract

INTRODUCTION

Most allergic rhinitis (AR) patients have moderate-to-severe, persistent disease. Meda Pharma's AzeFlu (MP-AzeFlu) combines intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel formulation in a single device to treat AR. This prospective, noninterventional study sought to assess the effectiveness of MP-AzeFlu (one spray/nostril twice daily; 548 µg AZE/200 µg FP daily dose) in relieving AR symptom severity.

METHODS

A visual analogue scale (VAS) was used prior to MP-AzeFlu treatment on days 0, 1, 3, 7, 14, 21, 28, 35, and 42 by 53 persistent AR (PER) patients seen in routine clinical practice in Ireland. An endoscopy was performed on days 0 and 28, and symptoms of edema, discharge, and redness were scored on a three-point scale (for both nostrils).

RESULTS

Patients using MP-AzeFlu experienced rapid VAS score reduction from 73.4 mm (standard deviation [SD], 20.3) at Day 0 to 31.5 mm (SD, 25.0) at day 28 (P < 0.0001) to 28.1 mm (SD, 24.1) at day 42 (P < 0.0001), a 45.3-mm reduction. On average, patients achieved a clinically relevant VAS score cutoff of 50 mm before Day 7. Total endoscopy score decreased from 7.5 mm (SD, 3.1) at baseline to 3.5 mm (SD, 2.5) at Day 28. The incidence of severe edema on endoscopy decreased from 53.1% at baseline to 3.8% at Day 28. A similar reduction in the incidence of thick/mucousy discharge (from 28.3% to 4.8%) and severe redness (from 34.9% to 0%) was also observed.

CONCLUSIONS

MP-AzeFlu provided effective, rapid control of PER as assessed by VAS in a real-world clinical setting in Ireland. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved mucosal appearance after 28 days. These results confirm the safety of MP-AzeFlu and exceed the efficacy demonstrated in phase 3 clinical studies for controlling AR in PER patients.

Authors+Show Affiliations

Bon Secours Consultant Private Clinic, Beacon ENT and Allergy Clinic at Beacon Hospital, Dublin, Ireland.Meda Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.Meda Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30306729

Citation

Kaulsay, Ranbir, et al. "Real-life Effectiveness of MP-AzeFlu in Irish Patients With Persistent Allergic Rhinitis, Assessed By Visual Analogue Scale and Endoscopy." Immunity, Inflammation and Disease, vol. 6, no. 4, 2018, pp. 456-464.
Kaulsay R, Nguyen DT, Kuhl HC. Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immun Inflamm Dis. 2018;6(4):456-464.
Kaulsay, R., Nguyen, D. T., & Kuhl, H. C. (2018). Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. Immunity, Inflammation and Disease, 6(4), 456-464. https://doi.org/10.1002/iid3.237
Kaulsay R, Nguyen DT, Kuhl HC. Real-life Effectiveness of MP-AzeFlu in Irish Patients With Persistent Allergic Rhinitis, Assessed By Visual Analogue Scale and Endoscopy. Immun Inflamm Dis. 2018;6(4):456-464. PubMed PMID: 30306729.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy. AU - Kaulsay,Ranbir, AU - Nguyen,Duc Tung, AU - Kuhl,Hans Christian, Y1 - 2018/10/11/ PY - 2018/08/14/received PY - 2018/09/04/accepted PY - 2018/10/12/pubmed PY - 2019/6/8/medline PY - 2018/10/12/entrez KW - Ireland KW - MP-AzeFlu KW - azelastine hydrochloride KW - endoscopy KW - fluticasone propionate KW - persistent allergic rhinitis SP - 456 EP - 464 JF - Immunity, inflammation and disease JO - Immun Inflamm Dis VL - 6 IS - 4 N2 - INTRODUCTION: Most allergic rhinitis (AR) patients have moderate-to-severe, persistent disease. Meda Pharma's AzeFlu (MP-AzeFlu) combines intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel formulation in a single device to treat AR. This prospective, noninterventional study sought to assess the effectiveness of MP-AzeFlu (one spray/nostril twice daily; 548 µg AZE/200 µg FP daily dose) in relieving AR symptom severity. METHODS: A visual analogue scale (VAS) was used prior to MP-AzeFlu treatment on days 0, 1, 3, 7, 14, 21, 28, 35, and 42 by 53 persistent AR (PER) patients seen in routine clinical practice in Ireland. An endoscopy was performed on days 0 and 28, and symptoms of edema, discharge, and redness were scored on a three-point scale (for both nostrils). RESULTS: Patients using MP-AzeFlu experienced rapid VAS score reduction from 73.4 mm (standard deviation [SD], 20.3) at Day 0 to 31.5 mm (SD, 25.0) at day 28 (P < 0.0001) to 28.1 mm (SD, 24.1) at day 42 (P < 0.0001), a 45.3-mm reduction. On average, patients achieved a clinically relevant VAS score cutoff of 50 mm before Day 7. Total endoscopy score decreased from 7.5 mm (SD, 3.1) at baseline to 3.5 mm (SD, 2.5) at Day 28. The incidence of severe edema on endoscopy decreased from 53.1% at baseline to 3.8% at Day 28. A similar reduction in the incidence of thick/mucousy discharge (from 28.3% to 4.8%) and severe redness (from 34.9% to 0%) was also observed. CONCLUSIONS: MP-AzeFlu provided effective, rapid control of PER as assessed by VAS in a real-world clinical setting in Ireland. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved mucosal appearance after 28 days. These results confirm the safety of MP-AzeFlu and exceed the efficacy demonstrated in phase 3 clinical studies for controlling AR in PER patients. SN - 2050-4527 UR - https://www.unboundmedicine.com/medline/citation/30306729/Real_life_effectiveness_of_MP_AzeFlu_in_Irish_patients_with_persistent_allergic_rhinitis_assessed_by_visual_analogue_scale_and_endoscopy_ L2 - https://doi.org/10.1002/iid3.237 DB - PRIME DP - Unbound Medicine ER -